Target type: biologicalprocess
Any process that decreases the rate, frequency, or extent of cartilage development, the process whose specific outcome is the progression of the cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate. [GOC:dph]
Negative regulation of cartilage development is a crucial process that fine-tunes the formation and maintenance of cartilage tissue. It involves a complex interplay of signaling pathways, transcription factors, and extracellular matrix components, ensuring that cartilage development occurs in a controlled and precise manner. This process is essential for skeletal development, joint function, and overall organismal growth. Here's a detailed breakdown of the biological mechanisms involved:
**1. Signaling Pathways:**
* **TGF-β (Transforming Growth Factor Beta) Pathway:** TGF-β plays a critical role in cartilage development by promoting chondrocyte differentiation and matrix synthesis. However, excessive TGF-β signaling can lead to hypertrophic chondrocyte differentiation, which is associated with cartilage degeneration and osteoarthritis. Negative regulators of the TGF-β pathway, such as Smad7 and the inhibitory Smads (Smad6 and Smad7), help to control the extent of TGF-β signaling, preventing its overactivation.
* **Wnt Signaling Pathway:** Wnt signaling is implicated in both cartilage formation and maintenance. The canonical Wnt pathway, mediated by β-catenin, promotes chondrocyte proliferation and differentiation. However, excessive Wnt signaling can inhibit chondrocyte differentiation and promote premature hypertrophic differentiation. Negative regulators of Wnt signaling, such as DKK1 (Dickkopf-1) and sFRP1 (secreted frizzled-related protein 1), act to modulate Wnt activity and prevent aberrant cartilage development.
* **Hedgehog Signaling Pathway:** The Hedgehog signaling pathway is known to influence chondrocyte proliferation and differentiation. Sonic hedgehog (Shh) is a key player in cartilage development, promoting chondrocyte proliferation and regulating chondrocyte differentiation. However, excessive Shh signaling can lead to hypertrophic chondrocyte differentiation and cartilage degeneration. Negative regulators of Hedgehog signaling, such as Gli3 and Patched1, act to fine-tune Shh activity and prevent excessive signaling.
**2. Transcription Factors:**
* **Sox9 (SRY-box containing gene 9):** Sox9 is a master regulator of chondrocyte differentiation, promoting the expression of cartilage-specific genes and inhibiting hypertrophic chondrocyte differentiation. Negative regulators of Sox9, such as Runx2 and PPARγ, can modulate Sox9 activity, contributing to the regulation of cartilage development.
* **Runx2 (Runt-related transcription factor 2):** Runx2 plays a crucial role in regulating chondrocyte hypertrophy and endochondral ossification. It promotes the expression of genes associated with chondrocyte hypertrophy and bone formation. Negative regulators of Runx2, such as Dlx5 and Osterix, can modulate Runx2 activity, influencing the timing and extent of chondrocyte hypertrophy.
**3. Extracellular Matrix (ECM) Components:**
* **Collagen Type II:** Collagen Type II is the primary component of the cartilage ECM, providing structural support and resilience to the tissue. Negative regulators of collagen type II synthesis, such as MMPs (matrix metalloproteinases) and ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs), can degrade the ECM and contribute to cartilage degeneration.
* **Aggrecan:** Aggrecan is a large proteoglycan that contributes to the hydration and shock-absorbing properties of cartilage. Negative regulators of aggrecan synthesis and stability, such as MMPs and ADAMTSs, can degrade aggrecan, leading to cartilage degradation and loss of function.
**4. Other Factors:**
* **Microenvironment:** The surrounding microenvironment, including mechanical forces, oxygen tension, and growth factors, can influence cartilage development.
* **Epigenetics:** Epigenetic modifications, such as DNA methylation and histone acetylation, can regulate gene expression and influence cartilage development.
* **Cell Cycle Control:** The regulation of cell cycle progression is crucial for cartilage development, ensuring proper cell division and differentiation.
**Conclusion:**
Negative regulation of cartilage development is a complex and multifaceted process involving multiple signaling pathways, transcription factors, ECM components, and other factors. These negative regulators act to fine-tune cartilage development, preventing aberrant growth, ensuring proper tissue formation and maintenance, and contributing to overall skeletal health. This precise control is essential for maintaining the integrity of cartilage tissue, preventing premature degeneration, and promoting optimal joint function throughout life.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cathepsin K | A cathepsin K that is encoded in the genome of human. [PRO:WCB, UniProtKB:P43235] | Homo sapiens (human) |
Retinoic acid receptor alpha | A retinoic acid receptor alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:P10276] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tryptamine | aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines | human metabolite; mouse metabolite; plant metabolite | |
am 580 | 4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist. Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source | amidobenzoic acid; tetralins | antineoplastic agent; retinoic acid receptor alpha/beta agonist |
bms 961 | BMS 961: a retinoic acid receptor gamma agonist; no further info available 10/2006 | ||
lg 100268 | LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source | ||
tazarotene | tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin. tazarotene: a topical acetylenic retinoid; a topical kerytolytic | acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane | keratolytic drug; prodrug; teratogenic agent |
adapalene | adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether. Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE. | adamantanes; monocarboxylic acid; naphthoic acid | dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug |
leupeptin | aldehyde; tripeptide | bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor | |
calpeptin | amino acid amide | ||
Pyrrolidine-1-carbonitrile | pyrrolidines | ||
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
tamibarotene | tamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine. tamibarotene: has retinoid-binding activity | dicarboxylic acid monoamide; retinoid; tetralins | antineoplastic agent; retinoic acid receptor alpha/beta agonist |
4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid | |||
cd 437 | CD 437: selective for retinoic acid receptors gamma CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells. | adamantanes; monocarboxylic acid; naphthoic acid; phenols | apoptosis inducer; retinoic acid receptor gamma agonist |
6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid | 6-(1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acid: reverses keratinization process in hamster tracheal organ culture; inhibits induction of ornithine decarboxylase; structure & RN given in first source; RN not in Chemline 12/5/83 | ||
cd 2019 | CD 2019: a retinoic acid receptor beta2 agonist; structure given in first source | ||
agn 193109 | AGN 193109: structure given in first source | ||
nsc13345 | NSC13345: structure in first source | amidobenzoic acid | |
tretinoin | all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). | retinoic acid; vitamin A | anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule |
bms 195614 | BMS 195614 : A carboxamide resulting from the formal condensation of the carboxy group of 5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxylic acid with the amino group of p-aminobenzoic acid. It is a neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). It displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. It antagonizes agonist-induced coactivator (CoA) recruitment. | benzoic acids; quinolines; secondary carboxamide | retinoic acid receptor alpha antagonist |
bms 961 | |||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
ac 55649 | 4'-octyl-4-biphenylcarboxylic acid: an RAR beta2 agonist; structure in first source | biphenyls; carboxybiphenyl | |
telaprevir | cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines | antiviral drug; hepatitis C protease inhibitor; peptidomimetic | |
sr 11217 | SR 11217: structure given in first source | ||
lg 100567 | ALRT 1550: ALRT1550 is (2E,4E,6E)-isomer; LG100567 is (2E,4E,6Z)-isomer; structure given in first source | ||
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid: RN refers to (E)-isomer; structure given in first source arotinoid acid : A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR). | benzoic acids; naphthalenes; retinoid | antineoplastic agent; retinoic acid receptor agonist; teratogenic agent |
agn 191659 | AGN 191659: a retinoid x receptor pan-agonist; structure in first source | ||
agn 191701 | AGN 191701: retinoid X receptors agonist; RN refers to (E)-isomer; structure given in first source | ||
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
agn 190121 | |||
lg100754 | LG 100754: retinoic acid receptors antagonist & agonist; a mixed function retinoid whose activity is dimer-selective; structure given in first source | ||
relacatib | relacatib: a cathepsin K inhibitor; structure in first source | ||
lg 1506 | |||
a-705253 | A-705253: structure in first source | ||
nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
bms453 | BMS 189453: structure in first source BMS-453 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). It is a potent retinoic acid receptor gamma (RARbeta) agonist that acts as an antagonist against RARalpha and RARgamma. | benzoic acids; dihydronaphthalenes; stilbenoid | retinoic acid receptor alpha antagonist; retinoic acid receptor beta agonist; retinoic acid receptor gamma antagonist; teratogenic agent |
hx 630 | HX 630: a retinoid X receptor ligand that functions as both an RAR synergist and peroxisome proliferator-activated receptor gamma synergist; structure in first source | ||
bms 204493 | BMS-493 : A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenylethynyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). | acetylenic compound; benzoic acids; dihydronaphthalenes; stilbenoid | retinoic acid receptor antagonist |
l 006235 | |||
l-873724 | L-873724: a selective inhibitor of cathepsin K; structure in first source | ||
sr 11302 | SR 11302: structure given in first source SR11302 : A retinoid that is all-trans-retinoic acid in which the methyl group at position 9 is replaced by a 4-methylphenyl group. It is an inhibitor of activator protein-1 which exhibits antitumour effects in vivo. | alpha,beta-unsaturated monocarboxylic acid; retinoid; toluenes | antineoplastic agent; AP-1 antagonist |
cd 666 | |||
odanacatib | odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source | ||
balicatib | balicatib: cathepsin K inhibitor | ||
agn 190205 | AGN 190205: inhibits vascular smooth muscle cell proliferation; structure in first source | ||
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection. | tripeptide; ureas | antiviral drug; hepatitis C protease inhibitor; peptidomimetic |
le 135 | LE 135: structure given in first source | dibenzodiazepine | |
ac 261066 | |||
PF-00835231 | PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity. | aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
mk-7009 | vaniprevir : An azamacrocyclic compound that is a hepatitis C virus (HCV) NS3/4A protease inhibitor which is approved for the treatment of hepatitis C virus infections in Japan. vaniprevir: inhibits hepatitis C virus NS3/4a protease | azamacrocycle; carbamate ester; cyclopropanes; N-sulfonylcarboxamide; pyrrolidinecarboxamide | antiviral drug; hepatitis C protease inhibitor |
vel-0230 | VEL-0230: a cathepsin K antagonist | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide | N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM). | aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |